Literature DB >> 8915758

Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase.

R Galli1, S Michelini, L Bartalena, R Massetani, L Pani, L Grasso, G B Cassano, E Martino, R H Purdy, L Murri.   

Abstract

The 3alpha-hydroxy metabolites of progesterone (P), 3alpha-hydroxy-5alpha-pregnan-20-one (allopregnanolone, A-PREG) and 3alpha-hydroxy-5beta-pregnan-20-one (pregnanolone, PREG), have been found to be among the most potent ligands of gamma-aminobutyric (GABA)-A receptors; in experimental animals, they have been found to have anxiolytic, hypnotic and anticonvulsant effects. Similar to those of the benzodiazepines and barbiturates that interact with GABA-A receptors. The present study was undertaken to determine plasma A-PREG and PREG concentrations in the luteal phase in women with partial epilepsy, in order to determine if an impaired metabolism of P occurs in this convulsive disorder. We measured plasma P, A-PREG and PREG levels in 15 women with partial epilepsy in the intercritical phase, and in 15 age-matched healthy women, during the luteal phase of the ovarian cycle (22nd-24th day). The mean plasma +/- S.E. A-PREG levels (three blood samples) were 0.7 +/- 0.6 ng/ml in the epileptic women and 0.5 +/- 0.2 ng/ml in controls, with no significant difference between the two groups (p = NS); the PREG levels were also similar (1.4 +/- 1 ng/ml and 1 +/- 1.1 ng/ml, respectively: p = NS). A significant correlation was found between P levels and both A-PREG and PREG levels (r = 0.72, p < 0.001 and r = 0.79, p < 0.001, respectively). There were no significant differences between the two groups in terms of serum adrenocorticotropic hormone, cortisol, dihydroepiandrosterone-sulfate, follicle stimulating hormone, prolactin, luteinizing hormone or estradiol levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8915758     DOI: 10.1007/bf01997786

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  21 in total

1.  The role of estrogens in catamenial exacerbation of epilepsy.

Authors:  J LOGOTHETIS; R HARNER; F MORRELL; F TORRES
Journal:  Neurology       Date:  1959-05       Impact factor: 9.910

Review 2.  Steroids and brain activity. Essential dialogue between body and mind.

Authors:  M D Majewska
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

3.  Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.

Authors:  M D Majewska; N L Harrison; R D Schwartz; J L Barker; S M Paul
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

4.  Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy.

Authors:  T Bäckström; B Zetterlund; S Blom; M Romano
Journal:  Acta Neurol Scand       Date:  1984-04       Impact factor: 3.209

Review 5.  Neuroactive steroids.

Authors:  S M Paul; R H Purdy
Journal:  FASEB J       Date:  1992-03       Impact factor: 5.191

Review 6.  Epilepsy, sex hormones, and antiepileptic drugs.

Authors:  R H Mattson; J A Cramer
Journal:  Epilepsia       Date:  1985       Impact factor: 5.864

7.  Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects.

Authors:  U Bonuccelli; G Murialdo; E Martino; S Lecchini; M L Bonura; G Bambini; L Murri
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

8.  GABA-dependent modulation of the Cl- ionophore by steroids in rat brain.

Authors:  K W Gee; W C Chang; R E Brinton; B S McEwen
Journal:  Eur J Pharmacol       Date:  1987-04-29       Impact factor: 4.432

9.  Prolactin secretion in epileptic subjects treated with phenobarbital: sex differences and circadian periodicity.

Authors:  U Bonuccelli; G Murialdo; G Rossi; M L Bonura; A Polleri; L Murri
Journal:  Epilepsia       Date:  1986 Mar-Apr       Impact factor: 5.864

10.  Anticonvulsant profile of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one.

Authors:  D Belelli; M B Bolger; K W Gee
Journal:  Eur J Pharmacol       Date:  1989-07-18       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.